SecBot SecBot
8-K ·Filed May 15, 2026

CCCC

C4 Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001628280-26-035542
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

This is a routine internal role consolidation with no financial or operational implications. The recent DEFA14A proxy solicitation (April 29) suggests board-level activity, but this filing is unrelated. No trading action warranted.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.22
T+0 close · May 15, 2026 · via day close
Latest settled
+21.12%
T+60 · $3.90
Vs SPY
+16.27%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $3.22entry
  2. T+1 · 6mo ago −3.42%α −2.77% · $3.11
  3. T+5 · 6mo ago +8.39%α +6.77% · $3.49
  4. T+20 · 5mo ago +19.25%α +17.67% · $3.84
  5. T+60 · 3mo ago +21.12%α +16.27% · $3.90

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C4 Therapeutics disclosed the departure of Chief Accounting Officer Mark Mossler, effective May 15, 2026, with no disagreement cited. CFO Kendra R. Adams has been appointed as the new principal accounting officer without additional compensation. This is a routine internal role consolidation, not a red-flag departure.

Key Facts

  • Mark Mossler will cease serving as Chief Accounting Officer effective May 15, 2026.
  • Departure is explicitly stated as not due to any disagreement with the company or board on financial reporting, operations, policies, or practices.
  • CFO Kendra R. Adams has been designated as the new principal accounting officer, effective May 15, 2026.
  • Adams will receive no additional compensation for assuming the principal accounting officer role.
  • A DEFA14A proxy filing from April 29, 2026 (16 days prior) indicates recent contested election or solicitation activity.

Financial Impact

No financial impact. Role consolidation with no compensation change.

Risk Factors

  • No material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-035542
Document: 0001628280-26-035542-index-headers.html0001628280-26-035542
Document: 0001628280-26-035542-index.html0001628280-26-035542
Document: 0001628280-26-035542.txt0001628280-26-035542

Track record

19 reports on CCCC

Performance horizon

5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +46.29% at T+60 after the Apr 9, 2026 report. 5 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.71 Now $2.65 −2.03% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $2.76 Now $2.65 −3.99% settles Nov 20
  3. Nov 6, 202610d ago Institutional Cluster Neutral 2/10 Entry $3.10 to $2.76 Now $2.65 −14.52% ▼ −10.97% −13.56% vs SPY
  4. Nov 5, 202611d ago 8-K Neutral 4/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $2.95 to $2.77 Now $2.65 −10.17% ▼ −6.10% −9.39% vs SPY
  6. Sep 25, 20267w ago 8-K Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  7. Sep 25, 20267w ago Press Release Neutral 4/10 Entry $2.98 to $2.95 Now $2.65 −11.07% ▼ −1.01% −0.79% vs SPY
  8. Aug 14, 202613w ago 144 Neutral 3/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  9. Aug 14, 202613w ago Institutional Cluster Bullish 6/10 Entry $4.27 to $4.10 Now $2.65 −37.87% ▼ −3.87% −2.68% vs SPY
  10. Aug 11, 202613w ago 8-K Neutral 5/10 Entry $3.87 to $4.18 Now $2.65 −31.52% ▲ +8.01% +8.41% vs SPY
Showing 10 of 19

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026